TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05549037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Sintilimab
Description: One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Sintilimab
Description: One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.
Study: NCT05841030

Intervention type: OTHER
Intervention: No Intervention
Description: There is no interventional treatment administered to the participants as a part of this study.
Study: NCT05659602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Nasal Spray
Description: HH-120 Nasal Spray 8-10 times per day for 6 consecutive days
Study: NCT05554237

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07612577
Description: PF-07612577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06264006
Description: PF-06264006
Study: NCT05661578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab and Atezolizumab IV FDC
Description: Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).
Study: NCT05921994

Intervention type: OTHER
Intervention: secukinumab
Description: Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.
Study: NCT06038188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT LESS Booster
Description: Patients allocated to the SIT LESS Booster group receive usual care in combination with the SIT LESS Booster program.~The SIT LESS Booster program consists of: 1) The use of the pocket-worn activity tracker (Activ8sit). The activity tracker can be connected to an app to track the daily sitting time. Besides, the device buzzes when a person sits more than 30 consective minutes a s a reminder to stand up and move; 2) Telephone consultation (TC1) during which the researcher and patients will reactivate knowledge on the detrimental health effects of SB, discuss patients' personal goals and motivation, and collaboratively set action plans for reducing SB in the upcoming week (±20 minutes); and 3) Weekly telephone calls (TC2 and TC3) to evaluate sedentery behaviour of the preceding week (±10 minutes).~The SIT LESS Booster will be delivered completely remote
Study: NCT05013450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: three q3w cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: three q3w cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade
Description: SOC immunotherapy with PD-1/PD-L1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 blockade
Description: SOC immunotherapy with PD-1/PD-L1 blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg daily injection for Three q3w cycles
Study: NCT05369052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: contezolid acefosamil (IV)/contezolid (PO)
Description: Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid (IV and PO)
Description: Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
Study: NCT06347172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge Intervention
Description: PCPs will receive an enhanced EHR alert (nudge) that triggers when a PCP opens an encounter for an eligible patient living with dementia (PLWD). The nudge will provide information about the risks of continued medication use as well as tips and tools to help providers discuss medication discontinuation with patients and care partners. Additionally, the providers will receive a brief message in their in-basket 10 days before the patient's appointment as a reminder.~Eligible PLWD of a randomized PCP will receive the nudge intervention which includes a brief recommendation for the PLWD (and care partner, if available) via the linked patient portal prior to upcoming visits (unless explicitly opted out by the PCP) to discuss medications with the PCP at the visit and link to a general handout about medications, unless explicitly opted out by the PCP. For PLWD without a portal account, the handout will be sent to their mailing address recorded in the EHR.
Study: NCT04768569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide 100Mg Cap
Description: ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide 100Mg Cap
Description: ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
Study: NCT04918186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg IV, 60 min day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg IV, 60 min day 1 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA3011
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA3021
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENB003
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: IV
Study: NCT06522360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given by vein
Study: NCT04916470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
Study: NCT05758545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COMS One device
Description: The COMS One device incorporates technologies for optical and magnetic stimulation. The optical stimulation component is designed to emit light by two types of light emitting diodes (LEDs) in the wavelength of 660 nm (red) and 830 nm (near infrared) range of the electromagnetic spectra. The magnetic stimulation component is generated by a coil emitting pulse modulated magnetic fields in the extremely low frequency (ELF) range of the electromagnetic spectra. The COMS One is a lightweight, portable device. The device is locally applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific feature that has been modified for the purpose of blinding is sensor detecting whether the device is lying on the skin.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The Sham device is a lightweight, portable device. The device is applied via a single use disposable component (COMStouch) that provides a base and sterile barrier for the unit. The device is attached via a single use strap (COMSfix). The device has been slightly adapted in order to make sure blinding is achieved/maintained. The specific features that have been modified for the purposes of blinding include the following: 1) therapeutic output, and 2) sensor detecting whether the device is lying on the skin.
Study: NCT06298903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Activation
Description: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip activation + Single leg balance
Description: Hip activation HEP: Sidelying hip abduction, side plank with hip abduction, clamshell (hip abduction + external rotation), side plan with clamshell, and quadruped fire hydrant exercises will be performed for 1 minute isometric holds, 2 times per week for 8 weeks.~Single leg balance: variety of single leg balance exercises with different upper extremity and lower extremity positions to provide different balance stimuli. Weeks are alternated performing these exercises with eyes open and eyes closed.
Study: NCT04695171

Intervention type: DEVICE
Intervention: LINX Reflux Management System
Description: The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire links to allow esophageal distention as the bolus passes by.

Intervention type: PROCEDURE
Intervention: Fundoplication
Description: A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.
Study: NCT05531149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimodulin
Description: IMP will be administered via IV infusion on 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (human albumin 1%)
Description: IMP will be administered via IV infusion on 5 consecutive days
Study: NCT06034405

Intervention type: DIAGNOSTIC_TEST
Intervention: Tc99-PYP or Tc99-HDMP Scan
Description: Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
Study: NCT05150704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
Study: NCT04791735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: * Installations of the patient: the position of the patient will depend on both extent of resection and location of the lesion.~* Absence of laparotomy with the exception of the extraction of the resected specimen and absence of costal retractors.~* Use of laparoscopic specific devices:~  * Use of multiple (3-7) ports depending on the operator's preference and technical difficulty (mainly 5-6 ports for major liver resection).~ * Use of a laparoscopic camera system with 0° or 30°~ * Use of a dedicated laparoscopic ultrasound probe.~ * Use of specific laparoscopic devices for coagulation, parenchymal transection and sealing.~* Placement of the resected specimen in a plastic bag and extraction without fragmentation, depending on the surgeon's preferenceand the diameter of the resected specimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: * Installation of the patient: patients will be placed in supine position, the surgeon operating on the right side of the patient and the assistant standing on the left side.~* Incision: the type of incision will depend on both the nature of the resection and the operator's preference. Various incisions such as bi subcostal incision, J-shaped incision, right subcostal incision and midline incision can be used.~* Use of open surgical instruments and devices for coagulation and parenchymal transection. These may include the crush-clamp technique or ultrasonic dissection for parenchymal transection, bipolar coagulation, clips, sutures or open vascular stapler for hemostasis and biliostasis.~* Methylene blue injection through the cystic drain to rule out biliary leakage will be performed depending on the surgeon's preference.
Study: NCT06090578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TabCAT Brain Health Assessment Clinical Pathway
Description: Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates who will then perform the TabCAT-BHA tablet-based test. The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline. The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate. Nursing support is available to support the PCP in making the diagnosis and to consult to the family via telephone post-diagnosis to address immediate care needs.
Study: NCT05796622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVST-Chatbot (HIV self-testing services with counseling provided by a Chatbot)
Description: Promote and implement HIVST-Chatbot

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIVST-OIC (HIV self-testing services with counseling provided by administrators)
Description: Promote and implement HIVST-OIC
Study: NCT06530381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises With Face-to-Face
Description: The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed face to face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises With Telerehabilitation
Description: The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed as telerehabilitation.
Study: NCT05470790

Intervention type: OTHER
Intervention: patient reported outcome measures
Description: Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.

Intervention type: OTHER
Intervention: patient reported outcome measures
Description: Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
Study: NCT05849064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Control
Description: Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Intervention
Description: Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
Study: NCT05551949

Intervention type: DRUG
Group type: OTHER
Intervention: Vaginal estradiol tablets
Description: Vaginal estradiol tablets (10mcg).
Study: NCT06530069

Intervention type: OTHER
Intervention: exposures
Description: exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.

Intervention type: OTHER
Intervention: exposures
Description: exposures: Ear cleaning, swimming, wearing earphones, diabetes, immunosuppression, antibiotic ear drops, narrowing of the external auditory canal, etc.
Study: NCT05462925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy.
Description: Functional electrical stimulation therapy will be delivered using the MyndMove system (MyndTec, Inc., Mississauga, Canada).
Study: NCT05180734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001/Placebo
Description: JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Description: JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Study: NCT05996003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Study: NCT06055920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowTriever System
Description: Mechanical Thrombectomy for pulmonary embolism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Agents
Description: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.~Anticoagulants are a group of medications that decrease your blood's ability to clot.
Study: NCT04320342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium Bromide
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
Study: NCT06055868

Intervention type: OTHER
Intervention: Group Meeting (Focus Group)
Description: Focus Group Discussions (FDGs) will be recorded, transcribed, and coded.

Intervention type: OTHER
Intervention: Questionnaires
Description: Given electronically or via phone by study team staff
Study: NCT05195151

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taking capsule containing probiotics or placebo
Description: The probiotics capsule containing two strains of probiotics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taking capsule containing probiotics or placebo
Description: The probiotics capsule containing two strains of probiotics.
Study: NCT06088810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoMPoSER intervention group
Description: Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.
Study: NCT05796739

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive stress test
Description: Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment without further testing
Description: Optimal medical treatment for primary prevention.
Study: NCT05481879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-101
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-101
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYNE-101
Description: Administered by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by IV infusion
Study: NCT05904119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Oral administration of Lomustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Oral administration of Lomustine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reirradiation
Description: Given at least 6 months after the end of prior radiotherapy
Study: NCT05084196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 5 mg capsule by mouth at bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Placebo capsule by mouth at bedtime